Journal of Pharmacy and Pharmaceutical Sciences最新文献

{"title":"Genetics, pharmacotherapy, and dietary interventions in childhood obesity.","authors":"Joe Eun Son","doi":"10.3389/jpps.2024.12861","DOIUrl":"10.3389/jpps.2024.12861","url":null,"abstract":"<p><p>Childhood obesity has emerged as a major global health issue, contributing to the increased prevalence of chronic conditions and adversely affecting the quality of life and future prospects of affected individuals, thereby presenting a substantial societal challenge. This complex condition, influenced by the interplay of genetic predispositions and environmental factors, is characterized by excessive energy intake due to uncontrolled appetite regulation and a Westernized diet. Managing obesity in childhood requires specific considerations compared with adulthood, given the vulnerability of the critical juvenile-adolescent period to toxicity and developmental defects. Consequently, common treatment options for adult obesity may not directly apply to younger populations. Therefore, research on childhood obesity has focused on genetic defects in regulating energy intake, alongside pharmacotherapy and dietary interventions as management approaches, with an emphasis on safety concerns. This review aims to summarize canonical knowledge and recent findings on genetic factors contributing to childhood obesity. Additionally, it assesses the efficacy and safety of existing pharmacotherapies and dietary interventions and suggests future research directions. By providing a comprehensive understanding of the complex dynamics of childhood obesity, this review aims to offer insights into more targeted and effective strategies for addressing this condition, including personalized healthcare solutions.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"12861"},"PeriodicalIF":5.5,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11165095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.","authors":"Konstantinos Zisis, Elpida Pavi, Mary Geitona, Kostas Athanasakis","doi":"10.3389/jpps.2024.12302","DOIUrl":"10.3389/jpps.2024.12302","url":null,"abstract":"<p><p><b>Objective:</b> This review aimed to assess the current use and acceptance of real-world data (RWD) and real-world evidence (RWE) in health technology assessment (HTA) process. It additionally aimed to discern stakeholders' viewpoints concerning RWD and RWE in HTA and illuminate the obstacles, difficulties, prospects, and consequences associated with the incorporation of RWD and RWE into the realm of HTA. <b>Methods:</b> A comprehensive PRISMA-based systematic review was performed in July 2022 in PubMed/Medline, Scopus, IDEAS-RePEc, International HTA database, and Centre for Reviews and Dissemination with <i>ad hoc</i> supplementary search in Google Scholar and international organization websites. The review included pre-determined inclusion criteria while the selection of eligible studies, the data extraction process and quality assessment were carried out using standardized and transparent methods. <b>Results:</b> Twenty-nine (<i>n</i> = 29) studies were included in the review out of 2,115 studies identified by the search strategy. In various global contexts, disparities in RWD utilization were evident, with randomized controlled trials (RCTs) serving as the primary evidence source. RWD and RWE played pivotal roles, surpassing relative effectiveness assessments (REAs) and significantly influencing decision-making and cost-effectiveness analyses. Identified challenges impeding RWD integration into HTA encompassed limited local data access, complexities in non-randomized trial design, data quality, privacy, and fragmentation. Addressing these is imperative for optimal RWD utilization. Incorporating RWD/RWE in HTA yields multifaceted advantages, enhancing understanding of treatment efficacy, resource utilization, and cost analysis, particularly via patient registries. RWE complements assessments of advanced therapy medicinal products (ATMPs) and rare diseases. Local data utilization strengthens HTA, bridging gaps when RCT data is lacking. RWD aids medical device decision-making, cancer drug reassessment, and indirect treatment comparisons. Challenges include data availability, stakeholder acceptance, expertise, and privacy. However, standardization, training, collaboration, and guidance can surmount these barriers, fostering enhanced RWD utilization in HTA. <b>Conclusion:</b> This study highlights the intricate global landscape of RWD and RWE acceptance in HTA. Recognizing regional nuances, addressing methodological challenges, and promoting collaboration are pivotal, among others, for leveraging RWD and RWE effectively in healthcare decision-making.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"12302"},"PeriodicalIF":5.5,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140121218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roxadustat Protects Against Hypoxia-Induced Organ Damage in Acute High-Altitude Models: A Pharmacodynamic Study","authors":"Frederik Olsen, Signe Larsen","doi":"10.51847/1mkgefmbqq","DOIUrl":"https://doi.org/10.51847/1mkgefmbqq","url":null,"abstract":"This study aimed to evaluate the protective effects of roxadustat against hypoxia-induced injury during rapid ascent to high altitude. BALB/C mice were randomly assigned to receive roxadustat at doses of 7.8, 15.6, or 31.2 mg/kg, or to control groups. The anti-hypoxic efficacy of roxadustat at the recommended dose was assessed using a controlled atmospheric pressure hypoxia model. Additionally, Wistar rats were randomly allocated to groups exposed to normal oxygen, hypoxia, acetazolamide, or rox","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"4 1","pages":"82-90"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://galaxypub.co/storage/files/article/55ee5fcc-3c60-4a3a-af57-af93bbafa655-cjiNvUtsTLRMxjoE/tBX98jskENU1yDh.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147879988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs.","authors":"Nastaran Hashemzadeh, Elaheh Rahimpour, Abolghasem Jouyban","doi":"10.3389/jpps.2023.12042","DOIUrl":"https://doi.org/10.3389/jpps.2023.12042","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.18433/jpps33121.].</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"26 ","pages":"12042"},"PeriodicalIF":2.7,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese medicine for treating aplastic anemia","authors":"Jing Guan, YiHui Zhao, Ting Wang, Rong Fu","doi":"10.3389/jpps.2023.11863","DOIUrl":"https://doi.org/10.3389/jpps.2023.11863","url":null,"abstract":"Aplastic anemia (AA) is a bone marrow failure disease caused by T cell hyperfunction. Although the overall response rate has been improved by immunosuppressive therapy (IST) plus Eltrombopag, 30% of patients have either no response or relapse. We therefore attempted to find other ways to improve the outcomes of AA patients. Traditional Chinese medicine has the advantages of low cost, reasonable effects, and few side effects. More and more clinical studies have confirmed that traditional Chinese medicine has a beneficial role in treating AA patients. This article reviews the potential mechanism of traditional Chinese medicine or its active ingredients in the treatment of AA. These include improving the bone marrow microenvironment, regulating immunity, and affecting the fate of hematopoietic stem cells. This provides useful information for further treatment of AA with integration of traditional Chinese and Western medicine and the development of new treatment strategies.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"66 50","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136281559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches","authors":"Omima S. Mohammed, Hany G. Attia, Bassim M. S. A. Mohamed, Marawan A. Elbaset, Hany M. Fayed","doi":"10.3389/jpps.2023.11808","DOIUrl":"https://doi.org/10.3389/jpps.2023.11808","url":null,"abstract":"Long-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Thus, continuous investigations for anti-fibrotic therapy are ongoing. The main theme of anti-fibrotic investigation during recent years is the rationale-based selection of treatment molecules according to the current understanding of the pathology of the disease. The research efforts are mainly toward repurposing current FDA-approved drugs targeting etiological molecular factors involved in developing liver fibrosis. In parallel, investigations also focus on experimental small molecules with evidence to hinder or reverse the fibrosis. Natural compounds, immunological, and genetic approaches have shown significant encouraging effects. This review summarizes the efficacy and safety of current under-investigation antifibrosis medications targeting various molecular targets, as well as the properties of antifibrosis medications, mainly in phase II and III clinical trials.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"37 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135476617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Level of service satisfaction of health BPJS patients with drug services at pharmacy X Sibolga City","authors":"Salmah Handayani Lubis, Fenny Hasanah, Eva Sartika Dasopang, Lathifur Rasyidah Tanjung","doi":"10.36490/journal-jps.com.v6i4.292","DOIUrl":"https://doi.org/10.36490/journal-jps.com.v6i4.292","url":null,"abstract":"Health-related issues are one of the most pressing needs of society. Indonesia has government-run health insurance that is directly under its control. When patients obtain services that are considered appropriate or above expectations, patient satisfaction is achieved. This research uses a survey research approach and is descriptive. Surveys distributed to respondents were used to collect data. Eighty respondents who met the inclusion requirements were sampled. The data used is primary data, information obtained directly from respondents, with data collection methods such as providing questionnaires, which are filled in by the respondents themselves and sent back to the researcher. The findings of the study, which were based on SPSS patient characteristics analysis, showed that females accounted for the most significant percentage of respondents (43), followed by the 46-55 years age group (32.5%) and housewives (27.5%), (n=26; 32.5%) had the highest hypertension diagnosis on SPSS analysis, while (n=18; 69%) had the highest drug name of amlodipine. The results, according to the Servqual model, showed that the guarantee dimension had the largest average of 98%(Assurance), while the responsiveness dimension had the lowest average of 92% (waiting time).","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"181 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135480592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uji antibakteri gel hand sanitizer ekstrak daun bawang (Allium fistulosum) tehadap bakteri Staphylococcus aureus","authors":"Nurasni Nurasni, Elfia Neswita","doi":"10.36490/journal-jps.com.v6i4.263","DOIUrl":"https://doi.org/10.36490/journal-jps.com.v6i4.263","url":null,"abstract":"Kemampuan penghambatan pertumbuhan bakteri dari gel handsanitizer adalah cukup baik. Daun bawang (Allium fistulosum) memiliki kandungan allicin yang dapat berfungsi sebagai penghambatan pertumbuhan bakteri Staphylococcus aureus. Tujuan dari penelitian ini adalah untuk menguii aktivitas antibakteri Staphylococcus aureus dari gel Hand Sanitizer yang mengandung estrak daun bawang. Prosedur meliputi pembuatan simplisia, karakterisasi dan pembuatan ekstrak melalui maserasi dengan konsentrasi 20%, 30% dan 40%, lalu dikakukan uji antibakteri dengan metode fifusi agar. Hasil uji tersebut didapatkan penghambatan bakteri dengan zona pada konsentrasi 20%, 30% dan 40% secara berturut-turut adalah 3,5 mm; 5,0 mm; dan 5,9 mm dengan kategori sedang. Kesimpulan dari penelitian ini adalah di dapatkan formulasi dengan konsentrasi terbaik adalah formulasi dengan konsentrasi ekstrak daun bawang sebesar dengan zona hambat bakteri Staphylococcus aureus adalah kategori sedang.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"56 16","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135684046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uji Aktivitas Antioksidan Ekstrak Bunga Telang (Clitoria ternatea L.) Dengan Metode DPPH (2,2 DIiphenyl 1-1 Pickrylhydrzyl)","authors":"Yulia Kusumanti, Eldesi Medisa Ilmawati, Usti Fina Hasanah Hasibuan","doi":"10.36490/journal-jps.com.v6i4.290","DOIUrl":"https://doi.org/10.36490/journal-jps.com.v6i4.290","url":null,"abstract":"Latar Belakang: Saat ini keadaan masyarakat Indonesia secara umum sedang memprihatinkan. Masyarakat ingin memilih menggunakan kendaraan bermotor untuk bepergian dibandingkan berjalan kaki atau bersepeda. Semua ini menyebabkan peningkatan jumlah radikal bebas dalam tubuh. Antioksidan diperlukan untuk mengatasi bahaya radikal bebas. Indonesia sangat kaya akan sumber daya alam termasuk berbagai tumbuhan, salah satunya adalah bunga telangi (clitoriaternatea l.) yang diduga memiliki aktivitasantioksidan.Tujuan Penelitian:untuk mengetahui aktivitas antioksidan pada bunga telang (Clitoria ternatea L.) dengan metode dpph (dua,dua-Diphenyl 1-1 Picrylhydrazyl).Metode:Ujiaktvitas antioksidan dapat dilakukan dengan memakai beberapa macam metode yaitu dpph, abts. Hasil : Penggolongan senyawa metabolit sekunder yang terdapat pada bunga telang (Clitoria ternatea L.) diantaranya adalah alkaloid, flavonoid, quinon, saponin, tanin, dan steroid dengan teknik yang digunakan dengan uji DPPH. Hasil sampel uji ekstrak bunga telang (Clitoria ternatea L.) mempunyai IC50 sebesar 356,65 ppm dan digolongkan sangat lemah. Penilaian nilai IC50 pada ekstak etanol bunga telang (Clitoria ternatea L.) dengan pelarut metanol memiliki nilai 95. Kesimpulan : Penilaian aktivitas antioksidan dapat dinilai dari IC50. Penilaian IC50 pada bunga telang (Clitoria ternatea L.) yang telah didapatkan hasil yang berbeda-beda, yaitu IC50 lemah dan kuat.Hal ini dapat dipengaruhi oleh panjang gelombang maksimum yang digunakan, serta suhu penyimpanan ekstrak suatu tanaman. Disamping itu, dibutuhkan pelarut yang baik, yaitu metanol, dalam pengukuran IC50 pada bunga telang (Clitoria ternatea L.) dengan menggunakan DPPH.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"66 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135975483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uji Aktivitas Antipiretik Ekstrak Daun Bidara (Ziziphus Spina Christi L) Terhadap Mencit Jantan (Mus Musculus)","authors":"Ferdinan Jalung, Mila Febrina Rindayani, Meity Christiani","doi":"10.36490/journal-jps.com.v6i4.289","DOIUrl":"https://doi.org/10.36490/journal-jps.com.v6i4.289","url":null,"abstract":"Latar Belakang; Indonesia memiliki ribuan tumbuhan yang tersebar di berbagai daerah. Kekayaan alam hayati yang ada dimanfaatkan sebagai bahan baku obat modern maupun tradisional. Masyarakat telah lama mengenal dan menggunakan obat tradisional untuk mengobati berbagai macam penyakit. Semakin mahalnya harga obat modern di pasaran menjadi salah satu alasan untuk menggali kembali penggunaan obat tradisional. Banyak jenis tanaman obat di Indonesia yang telah dimanfaatkan sebagai bahan baku obat, beberapa jenis tanaman tersebut bahkan telah teruji secara klinis kandungan fitokimia, khasiat dan keamanan penggunaannya..Tujuan; Untuk mengetahui ekstrak daun Bidara (Ziziphus spina-christi L.) memiliki aktivitas sebagai Antipiretik.Metode; Jenis penelitian ini adalah merupakan penelitian eksperimental. Ekstraksi dilakukan untuk menyari senyawa yang bersifat polar sehingga digunakan cairan etanol 60%. Hasil; Dari hasil penelitian yang telah dilakukan didapatkan rata-tara selisih penurunan suhu rata-rata antara waktu terhadap suhu demam dari menit ke 30 hingga menit ke 120 menit. Utnuk dosis 100 mg/30 g, 150 mg/30 g BB mencit, 200mg/30 g BB mencit, NaCMC dan Paracetamol pada menit ke 30 masing-masing berturut-turut sebesar 0,27, 0,37, 0,44, 0,04 dan 0,8oC. Untuk dosis 100 mg/30 g, 150 mg/30 g BB mencit, 200 mg/30 g BB mencit, NaCMC dan Paracetamol pada menit ke 60 masing- masing berturut-turut sebesar 0,6, 0,67, 0,94, 0,07 dan 1,47oC. Untuk dosis 100 mg/30 g, 150 mg/30 g BB mencit, 200 mg/30 g BB mencit, NaCMC dan Paracetamol pada menit ke 90 masing-masing berturut-turut sebesar 1,04, 1, 1,24, 0,07 dan 2,1oC.Kesimpulan; Ekstrak daun Bidara (Ziziphus spina-christi L.) memiliki aktivitas sebagai antipiretik pada mencit.Ekstrak daun Bidara (Ziziphus spina-christi L.) yang memiliki aktivitas antipiretik yaitu dosis 100 mg, 150 mg dan 200 mg/30 gram BB mencit.","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"66 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135975485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}